| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 University of Hacettepe, Faculty of Medicine, Department of Biochemistry, Ankara, Turkey; 2 University of Texas Southwestern Medical Center, Department of Cell Biology and 3 Harold Simmons Comprehensive Cancer Center, Dallas, Texas; and 4 Geron Corporation, Menlo Park, California
Requests for reprints: Jerry W. Shay, Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 77030. Phone: 214-648-3282; Fax: 214-646-8694; E-mail: Jerry.Shay{at}UTSOUTHWESTERN.EDU.
Differential regulation of telomerase activity in normal and tumor cells provides a rationale for the design of new classes of telomerase inhibitors. The telomerase enzyme complex presents multiple potential sites for the development of inhibitors. GRN163L, a telomerase enzyme antagonist, is a lipid-modified 13-mer oligonucleotide N3' 
P5'-thio-phosphoramidate, complementary to the template region of telomerase RNA (hTR). We evaluated both the in vitro and in vivo effects of GRN163L using A549-luciferase (A549-Luc) human lung cancer cells expressing a luciferase reporter. GRN163L (1 µmol/L) effectively inhibits telomerase activity of A549-Luc cells, resulting in progressive telomere shortening. GRN163L treatment also reduces colony formation in soft agar assays. Surprisingly, after only 1 week of treatment with GRN163L, A549-Luc cells were unable to form robust colonies in the clonal efficiency assay, whereas the mismatch control compound had no effect. Finally, we show that in vivo treatment with GRN163L is effective in preventing lung metastases in xenograft animal models. These in vitro and in vivo data support the development of GRN163L as a therapeutic for the treatment of cancer.
This article has been cited by other articles:
|
|
 |
|
  E. Brambilla and A. Gazdar Pathogenesis of lung cancer signalling pathways: roadmap for therapies Eur. Respir. J., June 1, 2009; 33(6): 1485 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Ghaffari, N. Shayan-Asl, A. H. Jamialahmadi, K. Alimoghaddam, and A. Ghavamzadeh Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival Ann. Onc., November 1, 2008; 19(11): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhao, E. Richer, P. P. Antich, and R. P. Mason Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI FASEB J, July 1, 2008; 22(7): 2445 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Targowski and K Jahnz-Rozyk Authors' reply Thorax, June 1, 2008; 63(6): 568 - 568. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chumsri, W. Matsui, and A. M Burger Therapeutic Implications of Leukemic Stem Cell Pathways Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Aubert and P. M. Lansdorp Telomeres and Aging Physiol Rev, April 1, 2008; 88(2): 557 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chumsri, W. Matsui, and A. M. Burger Therapeutic Implications of Leukemic Stem Cell Pathways Clin. Cancer Res., November 15, 2007; 13(22): 6549 - 6554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kelland Targeting the Limitless Replicative Potential of Cancer: The Telomerase/Telomere Pathway Clin. Cancer Res., September 1, 2007; 13(17): 4960 - 4963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Jackson, C.-H. Zhu, V. Paulson, L. Watkins, Z. G. Dikmen, S. M. Gryaznov, W. E. Wright, and J. W. Shay Antiadhesive Effects of GRN163L--An Oligonucleotide N3'->P5' Thio-Phosphoramidate Targeting Telomerase Cancer Res., February 1, 2007; 67(3): 1121 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Hochreiter, H. Xiao, E. M. Goldblatt, S. M. Gryaznov, K. D. Miller, S. Badve, G. W. Sledge, and B.-S. Herbert Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3184 - 3192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
